Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research

Authors: Park, Cheol-Kyu ^{a, b, c}, Khalil, Maryam ^{a, d}, Pham, Nhu-An ^a, Wong, Stephanie ^{a, e}, Ly, Dalam ^a, Sacher, Adrian ^{a, e, f}, Tsao, Ming-Sound ^{a, d, g, ∗}

Source: In JTO Clinical and Research Reports March 2025 6(3)

Healthcare utilization of lung cancer patients associated with exposure to fine particulate matter: A Korean cohort study

Authors: Oh, In‐Jae, Park, Cheol‐Kyu, Min, Kyoung‐Bok, Min, Jin‐Young, Chung, Chaeuk, Yoon, Seong‐Hoon, Kim, Changsoo, Yang, Sei‐Hoon

Source: Thoracic cancer. 14(27):2777-2784

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100193717424.0x000001&indx=1&recIds=ETOCvdc_100193717424.0x000001

Randomized, Multicenter, Phase 3 Study of Accelerated Fraction Radiation Therapy With Concomitant Boost to the Gross Tumor Volume Compared With Conventional Fractionation in Concurrent Chemoradiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer: The Korean Radiation Oncology Group 09-03 Trial

Authors: Kim, Yong-Hyub, Ahn, Sung-Ja, Moon, Sung Ho, Kim, Jin Hee, Kim, Young-Chul, Oh, In-Jae, Park, Cheol Kyu, Jeong, Jae-Uk, Yoon, Mee Sun, Song, Ju-Young, Suh, Chang-Ok, Cho, Kwan Ho, Park, Sun Hyo

Source: International journal of radiation oncology, biology, physics. 115(4):873-885

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100184087841.0x000001&indx=1&recIds=ETOCvdc_100184087841.0x000001

Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR

Authors: Park, Cheol-Kyu, Oh, Hyung-Joo, Kim, Young-Chul, Kim, Yong-Hyub, Ahn, Sung-Ja, Jeong, Won Gi, Lee, Jeong Yeop, Lee, Jae Cheol, Choi, Chang Min, Ji, Wonjun, Song, Si Yeol, Choi, Juwhan, Lee, Sung Yong, Kim, Hakyoung, Lee, Shin Yup, Park, Jongmoo, Yoon, Seong Hoon, Joo, Ji Hyeon, Oh, In-Jae

Source: In Journal of Thoracic Oncology August 2023 18(8):1042-1054

Ex vivo STAT3 phosphorylation in circulating immune cells: a novel biomarker for early cancer diagnosis and response to anti‐PD‐1 therapy.

Authors: Lee, Sung‐Woo, Kim, Young Ju, Jeong, Saei, Rho, Kyung Na, Noh, Jeong Eun, Kim, Hee‐Ok, Cho, Hyun‐Ju, Choi, Yoo Duk, Yang, Deok Hwan, Hwang, Eu Chang, Bae, Woo Kyun, Yun, Sook Jung, Yun, Ju Sik, Park, Cheol‐Kyu, Oh, In‐Jae, Cho, Jae‐Ho

Source: Cancer Communications; Jan2025, Vol. 45 Issue 1, p58-62, 5p

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment

Authors: Choi, Hayoung, Lee, Jae‐Kyeong, Oh, Hyung‐Joo, Kim, Min‐Seok, Kho, Bo Gun, Park, Cheol Kyu, Oh, In‐Jae, Kim, Young‐Chul

Source: Thoracic cancer. 12(10):1598-1604

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100120687310.0x000001&indx=1&recIds=ETOCvdc_100120687310.0x000001

Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum‐based doublet chemotherapy and immunotherapy (SPACE study)

Authors: Lee, Seung Hyeun, Park, Cheol‐Kyu, Lee, Sung Yong, Choi, Chang‐Min

Source: Thoracic cancer. 12(8):1264-1268

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100120236229.0x000001&indx=1&recIds=ETOCvdc_100120236229.0x000001

Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A

Authors: Park, Cheol‐Kyu, Lee, Sung‐Yong, Lee, Jae Cheol, Choi, Chang‐Min, Lee, Shin Yup, Jang, Tae‐Won, Oh, In‐Jae, Kim, Young‐Chul

Source: Thoracic cancer. 12(4):444-452

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100114870999.0x000001&indx=1&recIds=ETOCvdc_100114870999.0x000001

Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial.

Authors: Park, Cheol-Kyu¹ (AUTHOR) ckpark214@jnu.ac.kr, Jun, Ha Ra² (AUTHOR) 3143137@naver.com, Oh, Hyung-Joo¹ (AUTHOR) ohj4250@naver.com, Lee, Ji-Young² (AUTHOR) easy0@hanmail.net, Cho, Hyun-Ju¹ (AUTHOR) repair2799@hanmail.net, Kim, Young-Chul¹ (AUTHOR) kyc0923@jnu.ac.kr, Lee, Jeong Eun³ (AUTHOR) jelee0210@cnu.ac.kr, Yoon, Seong Hoon⁴ (AUTHOR) dognose79@naver.com, Choi, Chang Min⁵ (AUTHOR) ccm9607@gmail.com, Lee, Jae Cheol⁵ (AUTHOR) jclee@amc.seoul.kr, Lee, Sung Yong⁶ (AUTHOR) syl0801@korea.ac.kr, Lee, Shin Yup⁷ (AUTHOR) shinyup@knu.ac.kr, Chun, Sung-Min⁸ (AUTHOR) smchun@amc.seoul.kr, Oh, In-Jae¹ (AUTHOR) smchun@amc.seoul.kr

Source: Cells (2073-4409). May2023, Vol. 12 Issue 9, p1246. 20p.

Subject Terms: *NON-small-cell lung carcinoma, *HEMATOMA, *ATEZOLIZUMAB, *CELL-free DNA

Corrigendum to ‘Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research’ [JTO Clinical and Research Reports Volume 6 Issue 3 (2025) 100781]

Authors: Park, Cheol-Kyu ^{a, b, c}, Khalil, Maryam ^{a, d}, Pham, Nhu-An ^a, Wong, Stephanie ^{a, e}, Ly, Dalam ^a, Sacher, Adrian ^{a, e, f}, Tsao, Ming-Sound ^{a, d, g, ∗}

Source: In JTO Clinical and Research Reports May 2025 6(5)

A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.

Authors: Park, Cheol-Kyu¹ (AUTHOR), Jeon, Nakyung^2,3 (AUTHOR), Park, Hwa-Kyung¹ (AUTHOR), Oh, Hyung-Joo¹ (AUTHOR), Kim, Young-Chul¹ (AUTHOR), Jeon, Ha-Lim⁴ (AUTHOR), Kim, Yong-Hyub⁵ (AUTHOR), Ahn, Sung-Ja⁵ (AUTHOR), Oh, In-Jae¹ (AUTHOR) droij@jnu.ac.kr

Source: Cancers. Mar2023, Vol. 15 Issue 5, p1606. 14p.

Subject Terms: *LUNG cancer, *CONFIDENCE intervals, *CANCER chemotherapy, *MONOCLONAL antibodies, *ANTINEOPLASTIC agents, *RETROSPECTIVE studies, *TUMOR classification, *TREATMENT effectiveness, *COMPARATIVE studies, *DESCRIPTIVE statistics, *RESEARCH funding, *PROGRESSION-free survival, *PATIENT safety, *LONGITUDINAL method, *OVERALL survival, *PHARMACODYNAMICS

Blood-Based Biomarker Analysis for Predicting Efficacy of Chemoradiotherapy and Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer.

Authors: Park, Cheol-Kyu¹ (AUTHOR), Lee, Sung-Woo^2,3 (AUTHOR), Cho, Hyun-Ju¹ (AUTHOR), Oh, Hyung-Joo¹ (AUTHOR), Kim, Young-Chul¹ (AUTHOR), Kim, Yong-Hyub⁴ (AUTHOR), Ahn, Sung-Ja⁴ (AUTHOR), Cho, Jae-Ho^2,3,5 (AUTHOR), Oh, In-Jae¹ (AUTHOR) droij@chonnam.ac.kr

Source: Cancers. Feb2023, Vol. 15 Issue 4, p1151. 17p.

Subject Terms: *THERAPEUTIC use of monoclonal antibodies, *LUNG cancer, *RESEARCH, *PROGRAMMED death-ligand 1, *BLOOD platelets, *MONOCLONAL antibodies, *CHEMORADIOTHERAPY, *CANCER patients, *TUMOR classification, *TREATMENT effectiveness, *BLOOD cells, *RISK assessment, *RESEARCH funding, *TUMOR markers, *LONGITUDINAL method, *PHENOTYPES

Potentially fatal complications of systemic air embolism after computed tomography‐guided transthoracic needle biopsy in lung cancer harboring epithelial growth factor receptor mutation: A case report

Authors: Oh, Hyung‐Joo, Jeong, Won Gi, Lim, Yongwhan, Koh, Sang‐Joon, Lee, Sung Min, Kim, Min‐Seok, Koh, Bo‐Gun, Kim, Tae‐Ok, Choi, Yoo‐Duk, Oh, In‐Jae, Kim, Young‐Chul, Park, Cheol‐Kyu

Source: Thoracic cancer. 11(11):3401-3406

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100123855738.0x000001&indx=1&recIds=ETOCvdc_100123855738.0x000001

Risk factors for primary lung cancer among never-smoking women in South Korea: a retrospective nationwide population-based cohort study

Authors: Ko, Yoon Ho, Kim, Seung Joon, Kim, Wan-Seop, Park, Chan Kwon, Park, Cheol-Kyu, Suh, Yang-Gun, Eom, Jung Seop, Cho, Sukki, Hur, Jae Young, Hwang, Sung Ho

Source: Korean journal of internal medicine. 35(3):692-702

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN623666412&indx=1&recIds=ETOCRN623666412

Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer

Authors: Park, Seongho, Choi, Yoo‐Duk, Kim, Jieun, Kho, Bo‐Gun, Park, Cheol‐Kyu, Oh, In‐Jae, Kim, Young‐Chul

Source: Thoracic cancer. 11(2):408-414

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100099860258.0x000001&indx=1&recIds=ETOCvdc_100099860258.0x000001

Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma

Authors: Oh, In-Jae, Hur, Jae Young, Park, Cheol-Kyu, Kim, Young-Chul, Kim, Seung Joon, Lee, Min Ki, Kim, Hee Joung, Lee, Kye Young, Lee, Jae Cheol, Choi, Chang-Min

Source: In Clinical Lung Cancer September 2018 19(5):e775-e781

Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer

Authors: Park, Cheol-Kyu, Kim, Ji-Eun, Kim, Min-Seok, Kho, Bo-Gun, Park, Ha-Young, Kim, Tae-Ok, Shin, Hong-Joon, Cho, Hyun-Joo, Choi, Yoo-Duk, Oh, In-Jae, Kim, Young-Chul

Source: Journal of cancer research and clinical oncology. 145(8):2071-2082

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100118334825.0x000001&indx=1&recIds=ETOCvdc_100118334825.0x000001

Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer

Authors: Yoon, Joon‐Young, Park, Cheol‐Kyu, Choi, Yoo‐Duk, Oh, In‐Jae, Kim, Young‐Chul

Source: Thoracic cancer. 10(4):942-949

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100083731842.0x000001&indx=1&recIds=ETOCvdc_100083731842.0x000001

A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2

Authors: Park, Cheol-Kyu, Cho, Hyun-Ju, Choi, Yoo-Duk, Oh, In-Jae, Kim, Young-Chul

Source: Cancer research and treatment. 51(2):777-787

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN619642520&indx=1&recIds=ETOCRN619642520

Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial

Authors: Park, Cheol-Kyu, Oh, In-Jae, Kim, Kyu-Sik, Choi, Yoo-Duk, Jang, Tae-Won, Kim, Youn-Seup, Lee, Kwan-Ho, Shin, Kyeong-Cheol, Jung, Chi Young, Yang, Sei-Hoon, Ryu, Jeong-Seon, Jang, Seung-Hun, Yoo, Seung-Soo, Yong, Suk-Joong, Lee, Kye Young, In, Kwang-Ho, Lee, Min-Ki, Kim, Young-Chul

Source: In Clinical Lung Cancer July 2017 18(4):e289-e296